AMP-activated protein kinase regulates intraocular pressure, extracellular matrix, and cytoskeleton in trabecular meshwork

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 5, 2014, Pages 3127-3139

  Chatterjee, Ayan ^a   Villarreal Jr , Guadalupe ^a   Oh, Dong Jin ^a   Kang, Min Hyung ^a   Rhee, Douglas J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AMPK; Glaucoma; Intraocular pressure; POAG; RhoA; SPARC; TGF 2; Trabecular meshwork

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; OSTEONECTIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SCLEROPROTEIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA2;

ADENOVIRUS INFECTION; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE SEGMENT; AQUEOUS HUMOR; ARTICLE; CELL CULTURE; CENTRAL CORNEAL THICKNESS; CONTROLLED STUDY; CYTOSKELETON; EXTRACELLULAR MATRIX; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; INTRAOCULAR PRESSURE; MICROSCOPY; MOUSE; NONHUMAN; NORMAL HUMAN; OPTICAL COHERENCE TOMOGRAPHY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; TRABECULAR MESHWORK;

AMPK; GLAUCOMA; INTRAOCULAR PRESSURE; POAG; RHOA; SPARC; TGF-Β2; TRABECULAR MESHWORK;

ADULT; AGED; AGED, 80 AND OVER; AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AQUEOUS HUMOR; CELLS, CULTURED; CYTOSKELETON; EXTRACELLULAR MATRIX; GENE DELETION; HOMEOSTASIS; HUMANS; INTRAOCULAR PRESSURE; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN SUBUNITS; RIBONUCLEOTIDES; TRABECULAR MESHWORK; TRANSFORMING GROWTH FACTOR BETA2; YOUNG ADULT;

EID: 84900823316     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12755     Document Type: Article

References (91)

1. Nemesure B, Honkanen R, Hennis A, Wu SY, Leske MC; forBarbados Eye Studies Group. Incident open-angle glaucomaand intraocular pressure. Ophthalmology. 2007;114:1810-1815.
2. Larsson LI, Rettig ES, Brubaker RF. Aqueous flow in open-angleglaucoma. Arch Ophthalmol. 1995;113:283-286.
3. The advanced glaucoma intervention study (AGIS): 7. Therelationship between control of intraocular pressure andvisual field deterioration. The AGIS investigators. Am JOphthalmol. 2000;130:429-440.
4. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocularpressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268-1279.
5. Allingham RR, Liu Y, Rhee DJ. The genetics of primary openangleglaucoma: a review. Exp Eye Res. 2009;88:837-844.
6. Pederson JE, Gaasterland DE, MacLellan HM. Uveoscleralaqueous outflow in the rhesus monkey: importance of uvealreabsorption. Invest Ophthalmol Vis Sci. 1977;16:1008-1007.
7. Lei Y, Overby DR, Boussommier-Calleja A, Stamer WD, EthierCR. Outflow physiology of the mouse eye: pressure dependenceand washout. Invest Ophthalmol Vis Sci. 2011;52:1865-1871.
8. Aihara M, Lindsey JD, Weinreb RN. Aqueous humor dynamicsin mice. Invest Ophthalmol Vis Sci. 2003;44:5168-5173.
9. Bill A. Editorial: the drainage of aqueous humor. InvestOphthalmol. 1975;14:1-3.
10. Seiler T, Wollensak J. The resistance of the trabecularmeshwork to aqueous humor outflow. Graefes Arch ClinExp Ophthalmol. 1985;223:88-91.
11. Acott TS, Kingsley PD, Samples JR, Van Buskirk EM. Humantrabecular meshwork organ culture: morphology and glycosaminoglycansynthesis. Invest Ophthalmol Vis Sci. 1988;29:90-100.
12. Knepper PA, Farbman AI, Telser AG. Exogenous hyaluronidasesand degradation of hyaluronic acid in the rabbit eye. InvestOphthalmol Vis Sci. 1984;25:286-293.
13. Barany EH, Scotchbrook S. Influence of testicular hyaluronidaseon the resistance to flow through the angle of theanterior chamber. Acta Physiol Scand. 1954;30:240-248.
14. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrixmetalloproteinases activity on outflow in perfused humanorgan culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
15. Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS. Extracellularmatrix turnover and outflow resistance. Exp Eye Res. 2009;88:676-682.
16. Fuchshofer R, Tamm ER. Modulation of extracellular matrixturnover in the trabecular meshwork. Exp Eye Res. 2009;88:683-688.
17. Liton PB, Gonzalez P, Epstein DL. The role of proteolyticcellular systems in trabecular meshwork homeostasis. Exp EyeRes. 2009;88:724-728.
18. Tian B, Gabelt BT, Geiger B, Kaufman PL. The role of theactomyosin system in regulating trabecular fluid outflow. ExpEye Res. 2009;88:713-717.
19. Zhang M, Maddala R, Rao PV. Novel molecular insights intoRhoA GTPase-induced resistance to aqueous humor outflowthrough the trabecular meshwork. Am J Physiol Cell Physiol.2008;295:C1057-C1070.
20. Pattabiraman PP, Rao PV. Mechanistic basis of rho GTPaseinducedextracellular matrix synthesis in trabecular meshworkcells. Am J Physiol Cell Physiol. 2010;298:C749-C763.
21. Rohen JW. Presence of matrix vesicles in the trabecularmeshwork of glaucomatous eyes. Graefes Arch Clin ExpOphthalmol. 1982;218:171-176.
22. Stamer WD. The cell and molecular biology of glaucoma:mechanisms in the conventional outflow pathway. InvestOphthalmol Vis Sci. 2012;53:2470-2472.
23. Yan Q, Clark JI, Sage EH. Expression and characterization ofSPARC in human lens and in the aqueous and vitreous humors. Exp Eye Res. 2000;71:81-90.
24. Rhee DJ, Fariss RN, Brekken R, Sage EH, Russell P. Thematricellular protein SPARC is expressed in human trabecularmeshwork. Exp Eye Res. 2003;77:601-607.
25. Oh DJ, Kang MH, Ooi YH, Choi KR, Sage EH, Rhee DJ. Overexpression of SPARC in human trabecular meshworkincreases intraocular pressure and alters extracellular matrix. Invest Ophthalmol Vis Sci. 2013;54:3309-3319.
26. Haddadin RI, Oh DJ, Kang MH, et al. SPARC-null mice exhibitlower intraocular pressures. Invest Ophthalmol Vis Sci. 2009;50:3771-3777.
27. Swaminathan SS, Oh DJ, Kang MH, et al. Secreted protein, acidic and rich in cysteine (SPARC)-null mice exhibit moreuniform outflow. Invest Ophthalmol Vis Sci. 2013;54:2035-2047.
28. Rhee DJ, Haddadin RI, Kang MH, Oh DJ. Matricellular proteinsin the trabecular meshwork. Exp Eye Res. 2009;88:694-703.
29. Flugel-Koch C, Ohlmann A, Fuchshofer R, Welge-Lussen U, Tamm ER. Thrombospondin-1 in the trabecular meshwork:localization in normal and glaucomatous eyes, and inductionby TGF-beta1 and dexamethasone in vitro. Exp Eye Res. 2004;79:649-663.
30. Haddadin RI, Oh DJ, Kang MH, et al. Thrombospondin-1(TSP1)-null and TSP2-null mice exhibit lower intraocularpressures. Invest Ophthalmol Vis Sci. 2012;53:6708-6717.
31. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cellproliferation-AMPK as a therapeutic target for atherosclerosisand cancer. J Physiol. 2006;574:63-71.
32. Viollet B, Horman S, Leclerc J, et al. AMPK inhibition in healthand disease. Crit Rev Biochem Mol Biol. 2010;45:276-295.
33. Viollet B, Athea Y, Mounier R, et al. AMPK: lessons fromtransgenic and knockout animals. Front Biosci. 2009;14:19-44.
34. Hardie DG, Ross FA, Hawley SA. AMP-activated protein kinase:a target for drugs both ancient and modern. Chem Biol. 2012;19:1222-1236.
35. Barnes BR, Zierath JR. Role of AMP-activated protein kinase inthe control of glucose homeostasis. Curr Mol Med. 2005;5:341-348.
36. Li M, Verdijk LB, Sakamoto K, et al. Reduced AMPK-ACC andmTOR signaling in muscle from older men, and effect ofresistance exercise. Mech Ageing Dev. 2012;133:655-664.
37. Durante PE, Mustard KJ, Park SH, Winder WW, Hardie DG. Effects of endurance training on activity and expression ofAMP-activated protein kinase isoforms in rat muscles. Am JPhysiol Endocrinol Metab. 2002;283:E178-E186.
38. Park SH, Paulsen SR, Gammon SR, Mustard KJ, Hardie DG, Winder WW. Effects of thyroid state on AMP-activated proteinkinase and acetyl-CoA carboxylase expression in muscle. JAppl Physiol. 2002;93:2081-2088.
39. Qiang W, Weiqiang K, Qing Z, Pengju Z, Yi L. Aging impairsinsulin-stimulated glucose uptake in rat skeletal muscle viasuppressing AMPKalpha. Exp Mol Med. 2007;39:535-543.
40. Cacicedo JM, Benjachareonwong S, Chou E, Yagihashi N, Ruderman NB, Ido Y. Activation of AMP-activated proteinkinase prevents lipotoxicity in retinal pericytes. InvestOphthalmol Vis Sci. 2011;52:3630-3639.
41. Kubota S, Ozawa Y, Kurihara T, et al. Roles of AMP-activatedprotein kinase in diabetes-induced retinal inflammation. InvestOphthalmol Vis Sci. 2011;52:9142-9148.
42. Omae T, Nagaoka T, Tanano I, Yoshida A. Pioglitazone, aperoxisome proliferator-activated receptor-gamma agonist, induces dilation of isolated porcine retinal arterioles: role ofnitric oxide and potassium channels. Invest Ophthalmol VisSci. 2011;52:6749-6756.
43. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor inglaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727.
44. Yamamoto N, Itonaga K, Marunouchi T, Majima K. Concentrationof transforming growth factor beta2 in aqueous humor. Ophthalmic Res. 2005;37:29-33.
45. Ochiai Y, Ochiai H. Higher concentration of transforminggrowth factor-beta in aqueous humor of glaucomatous eyesand diabetic eyes. Jpn J Ophthalmol. 2002;46:249-253.
46. Fleenor DL, Shepard AR, Hellberg PE, Jacobson N, Pang IH, Clark AF. TGFbeta2-induced changes in human trabecularmeshwork: implications for intraocular pressure. InvestOphthalmol Vis Sci. 2006;47:226-234.
47. Bollinger KE, Crabb JS, Yuan X, Putliwala T, Clark AF, CrabbJW. Quantitative proteomics: TGFbeta(2) signaling in trabecularmeshwork cells. Invest Ophthalmol Vis Sci. 2011;52:8287-8294.
48. Kang MH, Oh DJ, Kang JH, Rhee DJ. Regulation of SPARC bytransforming growth factor b2 in human trabecular meshwork. Invest Ophthalmol Vis Sci. 2013;54:2523-2532.
49. Lim JY, Oh MA, Kim WH, Sohn HY, Park SI. AMP-activatedprotein kinase inhibits TGF-beta-induced fibrogenic responsesof hepatic stellate cells by targeting transcriptional coactivatorp300. J Cell Physiol. 2012;227:1081-1089.
50. Sasaki H, Asanuma H, Fujita M, et al. Metformin preventsprogression of heart failure in dogs: role of AMP-activatedprotein kinase. Circulation. 2009;119:2568-2577.
51. Myerburg MM, King JD Jr, Oyster NM, et al. AMPK agonistsameliorate sodium and fluid transport and inflammation incystic fibrosis airway epithelial cells. Am J Respir Cell MolBiol. 2010;42:676-684.
52. Park CS, Bang BR, Kwon HS, et al. Metformin reduces airwayinflammation and remodeling via activation of AMP-activatedprotein kinase. Biochem Pharmacol. 2012;84:1660-1670.
53. Mizutani J, Tokuda H, Matsushima-Nishiwaki R, et al. Involvement of AMP-activated protein kinase in TGF-betastimulatedVEGF synthesis in osteoblasts. Int J Mol Med. 2012;29:550-556.
54. Viollet B, Andreelli F, Jorgensen SB, et al. The AMP-activatedprotein kinase alpha2 catalytic subunit controls whole-bodyinsulin sensitivity. J Clin Invest. 2003;111:91-98.
55. Smith RS, Zabaleta A, Savinova OV, John SW. The mouseanterior chamber angle and trabecular meshwork developwithout cell death. BMC Dev Biol. 2001;1:3.
56. Wang WH, Millar JC, Pang IH, Wax MB, Clark AF. Noninvasivemeasurement of rodent intraocular pressure with a reboundtonometer. Invest Ophthalmol Vis Sci. 2005;46:4617-4621.
57. Saeki T, Aihara M, Ohashi M, Araie M. The efficacy of TonoLabin detecting physiological and pharmacological changes ofmouse intraocular pressure-comparison with TonoPen andmicroneedle manometery. Curr Eye Res. 2008;33:247-252.
58. Savinova OV, Sugiyama F, Martin JE, et al. Intraocular pressurein genetically distinct mice: an update and strain survey. BMCGenet. 2001;2:12.
59. Aihara M, Lindsey JD, Weinreb RN. Twenty-four-hour patternof mouse intraocular pressure. Exp Eye Res. 2003;77:681-686.
60. Danias J, Kontiola AI, Filippopoulos T, Mittag T. Method for thenoninvasive measurement of intraocular pressure in mice. Invest Ophthalmol Vis Sci. 2003;44:1138-1141.
61. Avila MY, Mitchell CH, Stone RA, Civan MM. Noninvasiveassessment of aqueous humor turnover in the mouse eye. Invest Ophthalmol Vis Sci. 2003;44:722-727.
62. Burstein NL. Preservative alteration of corneal permeability inhumans and rabbits. Invest Ophthalmol Vis Sci. 1984;25:1453-1457.
63. Oh DJ, Martin JL, Williams AJ, et al. Analysis of expression ofmatrix metalloproteinases and tissue inhibitors of metalloproteinasesin human ciliary body after latanoprost. InvestOphthalmol Vis Sci. 2006;47:953-963.
64. Mocanu JD, Yip KW, Alajez NM, et al. Imaging the modulationof adenoviral kinetics and biodistribution for cancer genetherapy. Mol Ther. 2007;15:921-929.
65. Mesonero A, Suarez DL, van Santen E, Tang DC, Toro H. Avianinfluenza in ovo vaccination with replication defectiverecombinant adenovirus in chickens: vaccine potency, antibodypersistence, and maternal antibody transfer. Avian Dis.2011;55:285-292.
66. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific methodfor activating AMP-activated protein kinase in intact cells? EurJ Biochem. 1995;229:558-565.
67. Sawada N, Itoh H, Miyashita K, et al. Cyclic GMP kinase andRhoA Ser188 phosphorylation integrate pro-and antifibroticsignals in blood vessels. Mol Cell Biol. 2009;29:6018-6032.
68. Rolli-Derkinderen M, Sauzeau V, Boyer L, et al. Phosphorylationof serine 188 protects RhoA from ubiquitin/proteasomemediateddegradation in vascular smooth muscle cells. CircRes. 2005;96:1152-1160.
69. Gayard M, Guilluy C, Rousselle A, et al. AMPK alpha 1-inducedRhoA phosphorylation mediates vasoprotective effect ofestradiol. Arterioscler Thromb Vasc Biol. 2011;31:2634-2642.
70. Millar JC, Clark AF, Pang IH. Assessment of aqueous humordynamics in the mouse by a novel method of constant-flowinfusion. Invest Ophthalmol Vis Sci. 2011;52:685-694.
71. Hall A. Rho family GTPases. Biochem Soc Trans. 2012;40:1378-1382.
72. Emerson RO, Sage EH, Ghosh JG, Clark JI. Chaperone-likeactivity revealed in the matricellular protein SPARC. J CellBiochem. 2006;98:701-705.
73. Martinek N, Shahab J, Sodek J, Ringuette M. Is SPARC anevolutionarily conserved collagen chaperone? J Dent Res.2007;86:296-305.
74. McCurdy S, Baicu CF, Heymans S, Bradshaw AD. Cardiacextracellular matrix remodeling: fibrillar collagens and secretedprotein acidic and rich in cysteine (SPARC). J Mol CellCardiol. 2010;48:544-549.
75. Chlenski A, Guerrero LJ, Salwen HR, et al. Secreted proteinacidic and rich in cysteine is a matrix scavenger chaperone. PLoS One. 2011;6:e23880.
76. Warden SM, Richardson C, O'Donnell J Jr, Stapleton D, KempBE, Witters LA. Post-translational modifications of the beta-1subunit of AMP-activated protein kinase affect enzyme activityand cellular localization. Biochem J. 2001;354:275-283.
77. Gregor M, Zeold A, Oehler S, et al. Plectin scaffolds recruitenergy-controlling AMP-activated protein kinase (AMPK) indifferentiated myofibres. J Cell Sci. 2006;119:1864-1875.
78. David R, Jenkins T. Genetic markers in glaucoma. Br JOphthalmol. 1980;64:227-231.
79. Sheffield VC, Stone EM, Alward WL, et al. Genetic linkage offamilial open angle glaucoma to chromosome 1q21-q31. NatGenet. 1993;4:47-50.
80. Wiggs JL, Haines JL, Paglinauan C, Fine A, Sporn C, Lou D. Genetic linkage of autosomal dominant juvenile glaucoma to1q21-q31 in three affected pedigrees. Genomics. 1994;21:299-303.
81. Wiggs JL, Del Bono EA, Schuman JS, Hutchinson BT, WaltonDS. Clinical features of five pedigrees genetically linked to thejuvenile glaucoma locus on chromosome 1q21-q31. Ophthalmology.1995;102:1782-1789.
82. Wojciechowski R, Stambolian D, Ciner E, Ibay G, Holmes TN, Bailey-Wilson JE. Genomewide linkage scans for ocularrefraction and meta-analysis of four populations in the myopiafamily study. Invest Ophthalmol Vis Sci. 2009;50:2024-2032.
83. Naiglin L, Gazagne C, Dallongeville F, et al. A genome widescan for familial high myopia suggests a novel locus onchromosome 7q36. J Med Genet. 2002;39:118-124.
84. Andersen JS, Pralea AM, DelBono EA, et al. A gene responsiblefor the pigment dispersion syndrome maps to chromosome7q35-q36. Arch Ophthalmol. 1997;115:384-388.
85. Sotirova VN, Irkec M, Percin EF, Bladow KM, Damji KF, Sarfarazi M. Molecular genetic study of families with pseudoexfoliationsyndrome (PEX) suggests two putative locations on 2p14-2cen and 2q35-q36 regions. Invest Ophthalmol VisSci. 1999;40:512.
86. Hitchings RA, Grierson I. Clinico pathological correlation ineyes with failed fistulizing surgery. Trans Ophthalmol Soc U K.1983;103(pt 1);84-88.
87. Miller MH, Joseph NH, Ennis KW, Grierson I, Hitchings RA. Ananimal model of filtration surgery. Trans Ophthalmol Soc U K.1985;104(pt 8);893-897.
88. Miller MH, Grierson I, Unger WI, Hitchings RA. Wound healingin an animal model of glaucoma fistulizing surgery in therabbit. Ophthalmic Surg. 1989;20:350-357.
89. Picht G, Welge-Luessen U, Grehn F, Lutjen-Drecoll E. Transforminggrowth factor beta 2 levels in the aqueous humor indifferent types of glaucoma and the relation to filtering blebdevelopment. Graefes Arch Clin Exp Ophthalmol. 2001;239:199-207.
90. Hawley SA, Fullerton MD, Ross FA, et al. The ancient drugsalicylate directly activates AMP-activated protein kinase. Science. 2012;336:918-922.
91. Keller KE, Vranka JA, Haddadin RI, et al. The effects oftenascin C knockdown on trabecular meshwork outflowresistance. Invest Ophthalmol Vis Sci. 2013;54:5613-5623.